Anti-Inflammatories: GMI-1070

GlycoMimetics’s lead anti-inflammatory compound, GMI-1070, inhibits a key early step in the inflammatory process leading to leukocyte adhesion and recruitment to inflamed tissue.  We have completed Phase I clinical trials to explore the use of GMI-1070 to treat vaso-occlusive crisis of sickle cell disease, with Phase 2 trials planned in 2009.

More about GMI-1070 >>

Anti-Infectives: GMI-1051

GMI-1051 targets infections caused by Pseudomonas aeruginosa, a bacterial cause of an increasing numbers of serious infections resistant to treatment with antibiotics.  This is a critical unmet need in a number of patient populations, including cystic fibrosis patients.

More about GMI-1051 >>